

New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma
Tweetorial #3 References: Subsequent-line Therapy

Tweet 4

Nadal R, Clara JA, Valderrama BP, Bellmunt J. Current therapy for metastatic urothelial carcinoma. *Hematol Oncol Clin North Am.* 2021;35:469-493.

Tweet 5

AstraZeneca. Voluntary withdrawal of Imfinzi indication in advanced bladder cancer in the US. Press release issued February 22, 2021. Accessed June 8, 2021. <https://www.astrazeneca.com/media-centre/press-releases/2021/voluntary-withdrawal-imfinzi-us-bladder-indication.html#>

Genentech. Genentech provides update on Tecentriq U.S. indication in prior-platinum treated metastatic bladder cancer. Press release issued March 8, 2021. Accessed June 8, 2021. <https://www.businesswire.com/news/home/20210307005061/en/Genentech-Provides-Update-on-Tecentriq-U.S.-Indication-in-Prior-Platinum-Treated-Metastatic-Bladder-Cancer>

Tweet 7

Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase 1b study. *J Clin Oncol.* 2017;35:2117-2124.

Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *N Engl J Med.* 2017;376:1015-1026.

Food and Drug Administration (FDA). FDA grants regular approval to enfortumab vedotin-ejfv for locally advanced or metastatic urothelial cancer. FDA press release, July 9, 2021. Accessed July 14, 2021. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-enfortumab-vedotin-ejfv-locally-advanced-or-metastatic-urothelial-cancer>.

Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial cancer. *N Engl J Med.* 2019;381:338-348.

Rosenberg JE, O'Donnell PH, Belar AF, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. *J Clin Oncol.* 2019;37:2592-2600.

Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 2017;18:312-322.

Tagawa ST, Balar AJ, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. *J Clin Oncol.* 2021 April 30. [Online ahead of print]

Tweet 8

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 3.2021 — April 22, 2021. Accessed June 8, 2021.
https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

Tweet 9

National Cancer Institute. Immune checkpoint inhibitors. Accessed June 8, 2021.
<https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune-checkpoint-inhibitor>.

Tweet 10

Bellmunt J, Necchi A, De Wit R, et al. Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. *J Clin Oncol*. 2021;39(Suppl 15):4532.

Tweet 11

Siefker-Radtke AO, Baron AD, Necchi A, et al. Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275. *J Clin Oncol*. 2021;39(Suppl 15):4524.

Tweet 12

Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. *Lancet Oncol*. 2018;19:51-64.

Tweet 13

Borosso-Sousa R, Tolaney SM. Clinical development of new antibody-drug conjugates in breast cancer: to infinity and beyond. *BioDrugs*. 2021;35:159-174.

Tweet 14

Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. *N Engl J Med*. 2021;384:1125-1135.

Tweet 15

Tagawa ST, Balar AV, Petrylak, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. *J Clin Oncol*. 2021 April 30. [Online ahead of print]

Tweet 16

Garje R, An J, Obeidat M, Kumar K, Yasin HA, Zakharia Y. Fibroblast growth factor receptor (FGFR) inhibitors in urothelial cancer. *Oncologist*. 2020;25:e1711-e1719.

Tweet 17

De Lorenzis E, Albo G, Longo F, Bebe C, Boeri L, Montanari E. Current knowledge on genomic profiling of upper tract urothelial carcinoma. *Genes (Basel)*. 2021;12:333.

Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial cancer. *N Engl J Med*. 2019;381:338-348.

Yu EY, Petrylak DP, O'Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2021;22:872-882.

Glossary

2L, second line
3L, third line
ADC, antibody drug conjugate
AEs, adverse events
AKT, protein kinase B
ASCO, American Society of Clinical Oncology
aUC, advanced urothelial carcinoma
Cis, cisplatin
CPS, combined positive score
CR, complete response
CTLA-4, cytotoxic T-lymphocyte antigen 4
DDMAVC, dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin
DOC, docetaxel
Dz, disease
EV, enfortumab vedotin
FGFR, fibroblast growth factor receptor
ICI(s), immune checkpoint inhibitor(s)
Ig, immunoglobulin
mAb, monoclonal antibody
MAPK, mitogen-activated protein kinase
mDOR, median duration of response
MMAE, monomethyl auristatin E
MOA, mechanism of action
mos, months
mOS, median overall survival
mPFS, median progression-free survival
mUC, metastatic urothelial carcinoma
NCCN, National Comprehensive Cancer Network
NP, nurse practitioner
ORR, objective response rate
OS, overall survival
P13K, phosphoinositide 3-kinase
PAX, paclitaxel
PD-1, programmed death cell protein 1
PD-L1, programmed death cell protein ligand 1
PLC, phospholipase C
PFS, progression-free survival
Ph, phase

PR, partial response
Prog, progressive
pt(s), patient(s)
RN, registered nurse
SG, sacituzumab govitecan
STAT, signal transducers and activators of transcription
TLR7, toll-like receptor 7
TKI, tyrosine kinase inhibitor
TRAEs, treatment-related adverse events
Trop-2, trophoblast antigen 2
tx, treatment/treated/therapy
UC, urothelial carcinoma
UTUC, upper-tract urothelial carcinoma
VFL, vinflunine
w/, with